Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check5 days agoChange DetectedAdded new help/navigation sections: How to Read a Study Record, Common Questions, and How to Join a Study, and standardized the Intervention/Treatment heading. The previous revision note Revision: v3.5.5 was removed and replaced with Revision: v3.6.0.SummaryDifference0.5%

- Check13 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5, indicating a newer page build. This reflects a newer version of the page release.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedUpdated revision tag from v3.5.3 to v3.5.4, indicating a newer version of the page metadata.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision tag updated from v3.5.2 to v3.5.3, indicating a small update to the page's revision history and release notes.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check84 days agoChange DetectedLayout and formatting updates to the study record page were observed. Core study content like eligibility criteria, outcomes, and enrollment status remains unchanged.SummaryDifference0.1%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.